Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. Signal., 8 March 2011
Vol. 4, Issue 163, p. ec72
[DOI: 10.1126/scisignal.4163ec72]


Cancer Biology Netting Pancreatic Cancer Genes

Paula A. Kiberstis

Science, AAAS, Washington, DC 20005, USA

Pancreatic neuroendocrine tumors (PanNETs) are aggressive human cancers that often develop silently and progress to untreatable metastatic disease before diagnosis. Using an exome sequencing strategy to identify recurrent somatic mutations in PanNETs, Jiao et al. (see the Perspective by Elsässer et al.) find that the most commonly mutated genes, affecting nearly 45% of the tumors, encode proteins implicated in chromatin remodeling. About 15% of the tumors had mutations altering the mammalian target of rapamycin (mTOR) signaling pathway. mTOR inhibitors are already being tested as cancer therapies, so the mutational status of the PanNETs could help to identify which patients are most likely to respond to these drugs.

Y. Jiao, C. Shi, B. H. Edil, R. F. de Wilde, D. S. Klimstra, A. Maitra, R. D. Schulick, L. H. Tang, C. L. Wolfgang, M. A. Choti, V. E. Velculescu, L. A. Diaz Jr., B. Vogelstein, K. W. Kinzler, R. H. Hruban, N. Papadopoulos, DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331, 1199–1203 (2011). [Abstract] [Full Text]

S. J. Elsässer, C. D. Allis, P. W. Lewis, New epigenetic drivers of cancers. Science 331, 1145–1146 (2011). [Abstract] [Full Text]

Citation: P. A. Kiberstis, Netting Pancreatic Cancer Genes. Sci. Signal. 4, ec72 (2011).

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882